Melatonin for Kids: Safe or Risky?

Melatonin has become the most commonly used sleep supplement in children in the United States. Survey data suggests that 1 in 5 school-age children and adolescents now take melatonin at least occasionally, and it has become many parents' first resort for bedtime struggles, sleep onset difficulties, and night waking. The perceived safety — it's natural, it's a hormone the body makes anyway, it's widely available without prescription — has led to its adoption well ahead of the evidence for its safety and efficacy in pediatric populations.

The American Academy of Pediatrics (AAP) and sleep medicine specialists have raised significant concerns about this pattern. Those concerns deserve careful examination.

What Melatonin Does — and Doesn't Do

Melatonin is a hormone produced by the pineal gland in response to darkness. It signals to the brain and body that night has arrived, helping to initiate the circadian shift toward sleep. Crucially, melatonin is a circadian signal, not a sedative — it shifts the timing of sleep onset rather than increasing sleep pressure or duration. This distinction matters enormously: melatonin is most useful when the problem is sleep timing (difficulty falling asleep at the desired time) and is much less useful for maintaining sleep or for children who simply don't feel tired at bedtime due to insufficient sleep pressure.

In children with circadian rhythm difficulties — particularly those with autism spectrum disorder (ASD) or ADHD, where melatonin rhythm disruption is common — melatonin supplementation has a reasonable evidence base. Multiple RCTs in children with ASD have found that low-dose melatonin (0.5–3 mg) improved sleep onset latency and total sleep time with minimal side effects over 3–6 month periods. This is the population where clinical use is most defensible.

The Dosing Problem

Consumer melatonin products designed for adults typically contain 3–10 mg per dose. In adults, even these doses are pharmacologically excessive — research consistently shows that the effective circadian signal dose for adults is 0.5–1 mg, not 5–10 mg. In children, the gap is even wider. Pediatric pharmacologists generally recommend starting at 0.5 mg and rarely exceeding 3 mg in children, with timing of administration (30–60 minutes before desired sleep onset) being critical.

The products most parents reach for — gummy melatonin supplements specifically marketed with children's branding — frequently contain 1–5 mg per gummy, with inconsistent actual content. Cohen et al. (JAMA 2023, PMID 37097570) analysed 25 melatonin gummy products sold in the US and found that 22 of 25 had quantified melatonin content deviating from the label (range 74–347% of labeled amount); one "melatonin" product contained no detectable melatonin. A separate analysis by Erland & Saxena (J Clin Sleep Med 2017, PMID 28095978) of 31 products found content ranging from −83% to +478% of label and detected serotonin in a quarter of them. Parents giving children "1 gummy" may be administering several times the effective pediatric dose, and CDC surveillance documented a rise in pediatric melatonin-related poison control calls of roughly 530% between 2012 and 2021 (Lelak et al., MMWR 2022, PMID 35653308).

Dependency and Developmental Concerns

Melatonin itself does not cause physiological addiction in the pharmacological sense. However, behavioral dependency is a well-documented clinical concern: children who receive melatonin every night may not develop the natural ability to self-regulate sleep onset, become reliant on the external signal, and struggle to fall asleep without it when the supplement is discontinued. Sleep medicine specialists uniformly emphasize that sleep hygiene and behavioral interventions (consistent schedules, appropriate light exposure, no screens before bed) should be the first-line approach, with melatonin as a short-term adjunct, not a nightly indefinite intervention.

The AAP's 2023 position: while melatonin can be appropriate for specific clinical uses in children with sleep disorders — particularly in ASD and ADHD — there is insufficient evidence to support long-term nightly use in otherwise healthy children with behavioral sleep difficulties. Parents should consult a pediatrician before giving melatonin to children under 3, use the lowest effective dose, set a defined treatment duration (weeks, not indefinitely), and pair it with consistent behavioral sleep strategies.

Practical Guidance for Parents

• First-line approach: Behavioral interventions — consistent sleep schedule, dark and cool room, no screens 1 hour before bed, relaxing pre-sleep routine. These address the root cause, not just the symptom.
• If melatonin is used: Consult a pediatrician first. Start at 0.5–1 mg, given 30–60 minutes before desired sleep time. Use pharmaceutical-grade products with verified content rather than gummies.
• Duration: Short courses (2–4 weeks) to help reset a disrupted schedule, not indefinite nightly use.
• Age: Do not use in children under 3 without specific medical guidance. Most benefit evidence is in school-age children with neurodevelopmental conditions.
• Not appropriate for: Night waking, early morning waking, or general resistance to sleep — these have different mechanisms that melatonin does not address.